EDMONTON, Alberta, Oct. 2 /PRNewswire-FirstCall/ -- Medical Services International Inc. is pleased to announce that the demand for its VScan Dengue Fever Kit is increasing. Dengue Fever is spreading across Latin America and the Caribbean in one of the worst outbreaks in decades causing agonizing joint pain for hundreds of thousands of people and killing 200 people so far this year.
This year so far 630,356 cases have been reported in the Americas and with the upcoming rainy season, cases are expected to double. This does not take into account the cases in SE Asia. The danger is that Doctors don’t recognize Dengue Fever. There are very few laboratories capable of testing for Dengue Fever, and the ones available take up to 8 weeks to complete the testing. By then it is too late for treatment.
There is no drug for Dengue Fever but early diagnosis resulting in proper treatment including rest, IV fluids and pain relief can reduce death rates to about 1%.
Dengue Fever is mosquito borne and is starting to spread into the southwestern United States.
The VScan Dengue Fever kit gives results in under 20 minutes and is accurate greater than 99% of the time. Early diagnosis with the VScan Dengue Fever kit allows for immediate treatment and reduces the severity and convalescence of the Dengue Fever patient.
Medical Services International Inc. trades in the United States on the NQB Pink Sheets under the symbol “MSITF”. For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com or http://www.minerva-biotech.com.
NOTE: Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
CONTACT: Robert Talbot, +1-780-430-6363, for Medical Services
International Inc.
Web site: http://www.medicalservicesintl.com/
http://www.minerva-biotech.com/
